Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that the first of four Phase 3 trials of its lead investigational product Contrave(R) (naltrexone sustained release (SR)/bupropion SR) met its co-primary and key secondary endpoints, showing a significant reduction in body weight, improvements in markers of cardiovascular risk and reductions in selected food craving measures.

In this trial, which included an intensive diet and exercise behavior modification regimen, obese patients treated with Contrave, based on intent-to-treat (ITT) and completer analyses, lost an average of 20.3 pounds to 25.0 pounds, or 9.3% to 11.5% of their baseline body weight, versus 11.0 pounds to 16.0 pounds, or 5.1% to 7.3% of baseline body weight, for patients treated with placebo. In addition, in the categorical weight reduction analysis, the percentage of patients who lost greater than or equal to 10% of their body weight was 20.2% in the placebo group compared to 41.5% in the Contrave group. We believe these results satisfy the categorical FDA efficacy benchmark for clinically significant weight loss. All of these findings were highly statistically significant (p<0.001).

Contrave was generally well tolerated by patients. The overall safety profile of Contrave was consistent with its individual components, naltrexone and bupropion, two drugs that have been used separately in patients for over 20 years. Treatment with Contrave was not associated with increases in symptoms of depression, suicidality or worsening of mean blood pressure.

"The results of this trial indicate that additional, clinically significant weight loss can be achieved when Contrave is added to a rigorous program of diet and exercise," said Eduardo Dunayevich, Chief Medical Officer, Orexige
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 The UPMC Center for Health Security ... the Emerging Leaders in Biosecurity Initiative (ELBI). As part ... field of biosecurity, UPMC has selected 28 US and ... of backgrounds, including biological science, medicine, policy, the military, ... "With the vision and support of the Defense Threat ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biologics and Biosimilars ... , The Global Biologics and ... in-depth study on the current state of the ... provides a basic overview of the industry including ...
(Date:3/4/2015)... , March 4, 2015 AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... and breakthrough pain, today announced that it will ... after market close on Monday, March 9th, 2015. ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biologics and Biosimilars Industry Report 2015-2020 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
... Epeius Biotechnologies,Corporation announced today the issue of ... in vivo. This patent provides additional,intellectual property ... embodied in the company,s leading anti-cancer agent,Rexin-G. ... Epeius,tumor-targeted gene delivery system enables Rexin-G to ...
... physicists have shown that in graphene the intrinsic limit ... material conducts electricity, is higher than any other known ... graphite, is a new material which combines aspects of ... the journal Nature Nanotechnology, indicate that graphene holds great ...
... March 24 Bio Career Center,( http://www.BioCareerCenter.com ), ... life-science professionals, has created a new tool to ... "Bio Skills Select" will allow companies to ... prospective candidates to answer. These,questions will range from ...
Cached Biology Technology:Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo 2UM physicists show electrons can travel over 100 times faster in graphene than in silicon 2UM physicists show electrons can travel over 100 times faster in graphene than in silicon 3Bio Career Center Develops New Tool to Assist in Employer/Candidate Match 2
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... 26, 2015   Epic Sciences , a precision diagnostics ... that Murali Prahalad , Ph.D., president and CEO, is ... (PMWC) 2015: Silicon Valley, which is taking place at ... on January 26-28, 2015. Dr. ... as Biomarkers." Last year, Epic Sciences was a finalist in ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... methods, such like mitochondrial DNA analysis, to differentiate ... a flashy symbol of modern science cleverly exploited ... by laboratory scientists to draw attention of government ... picture painted by these methods may be false, ...
... Scientist Jiř Friml from VIB and Ghent University, both ... Krber European Science Award, worth 750 000 euro. The ... particularly innovative research projects. Friml gets the prize for ... "Friml,s work on the genetic, molecular and cellular ...
... in protecting against cancer given that it prevents cancer-causing ... to the proliferation of tumour cells. UAB lecturer Ignasi ... research team, the study served to discover that this ... activated during the formation process of ova and spermatozoids. ...
Cached Biology News:Molecular methods are not sufficient in systematics and evolution 2Molecular methods are not sufficient in systematics and evolution 3VIB-UGent scientist Jiri Friml receives Koerber European Science Award 2010 2New function discovered in cancer prevention protein 2
... cDNA Labeling System - dCTP with ... For the generation and purification of ... packaged together for complete cDNA labeling ... be used for performing labeling reactions ...
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... with CyScribe GFX Purification Kit, 24 ... of Cy3- and Cy5-labeled cDNA.Optimized reagents ... labeling and purification.Flexible and optimized protocols ... reactions with either Cy3- or Cy5-labeled ...
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
Biology Products: